全球人类乳头瘤病毒 (HPV) 基因分型服务的持续改进:2022 年和 2023 年 HPV LabNet 国际能力研究。

IF 6.8 3区 医学 Q1 VIROLOGY Journal of Medical Virology Pub Date : 2024-10-22 DOI:10.1002/jmv.70022
Laila Sara Arroyo Mühr, Carina Eklund, Camilla Lagheden, Emel Yilmaz, Ola Forslund, Marina Lilja, Joakim Dillner
{"title":"全球人类乳头瘤病毒 (HPV) 基因分型服务的持续改进:2022 年和 2023 年 HPV LabNet 国际能力研究。","authors":"Laila Sara Arroyo Mühr,&nbsp;Carina Eklund,&nbsp;Camilla Lagheden,&nbsp;Emel Yilmaz,&nbsp;Ola Forslund,&nbsp;Marina Lilja,&nbsp;Joakim Dillner","doi":"10.1002/jmv.70022","DOIUrl":null,"url":null,"abstract":"<p>The International Human Papillomavirus (HPV) Reference Center launches annual global HPV genotyping proficiency panels to enhance the precision and international standardization of HPV genotyping services. This study aims to assess the proficiency levels achieved in the global HPV genotyping proficiency panels conducted in 2022 and 2023, and to evaluate trends in performance over time. The proficiency panels comprised 44 blinded samples each, including 40 samples containing various purified plasmids corresponding to HPV types combined with human DNA, plus four control samples (one negative control and three extraction controls). Proficiency required a sensitivity of 50 International Units (IU)/5 µL for HPV 16 and HPV 18 500 IU/5 µL for HPVs 6, 11, 31, 33, 45, 52, and 58 and 500 genome equivalents (GE)/5 µL for other HPV types in both single and multiple infections, while avoiding false positivity. In 2022, 78 laboratories submitted a total of 154 data sets, and in 2023, 81 laboratories contributed 141 data sets. Most data sets (87%, 258/295) utilized commercially available HPV assays. Proficiency was common, with 77% of data sets meeting the proficiency criteria in 2022 and 79% in 2023. False positive results significantly decreased from 22% in 2022 to 13% in 2023. The high proficiency and increasing specificity in HPV genotyping services indicates progress toward more reliable HPV testing. High accuracy is crucial for supporting global efforts in HPV and cervical cancer elimination.</p>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"96 10","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.70022","citationCount":"0","resultStr":"{\"title\":\"Continuous Global Improvement of Human Papillomavirus (HPV) Genotyping Services: The 2022 and 2023 HPV LabNet International Proficiency Studies\",\"authors\":\"Laila Sara Arroyo Mühr,&nbsp;Carina Eklund,&nbsp;Camilla Lagheden,&nbsp;Emel Yilmaz,&nbsp;Ola Forslund,&nbsp;Marina Lilja,&nbsp;Joakim Dillner\",\"doi\":\"10.1002/jmv.70022\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The International Human Papillomavirus (HPV) Reference Center launches annual global HPV genotyping proficiency panels to enhance the precision and international standardization of HPV genotyping services. This study aims to assess the proficiency levels achieved in the global HPV genotyping proficiency panels conducted in 2022 and 2023, and to evaluate trends in performance over time. The proficiency panels comprised 44 blinded samples each, including 40 samples containing various purified plasmids corresponding to HPV types combined with human DNA, plus four control samples (one negative control and three extraction controls). Proficiency required a sensitivity of 50 International Units (IU)/5 µL for HPV 16 and HPV 18 500 IU/5 µL for HPVs 6, 11, 31, 33, 45, 52, and 58 and 500 genome equivalents (GE)/5 µL for other HPV types in both single and multiple infections, while avoiding false positivity. In 2022, 78 laboratories submitted a total of 154 data sets, and in 2023, 81 laboratories contributed 141 data sets. Most data sets (87%, 258/295) utilized commercially available HPV assays. Proficiency was common, with 77% of data sets meeting the proficiency criteria in 2022 and 79% in 2023. False positive results significantly decreased from 22% in 2022 to 13% in 2023. The high proficiency and increasing specificity in HPV genotyping services indicates progress toward more reliable HPV testing. High accuracy is crucial for supporting global efforts in HPV and cervical cancer elimination.</p>\",\"PeriodicalId\":16354,\"journal\":{\"name\":\"Journal of Medical Virology\",\"volume\":\"96 10\",\"pages\":\"\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2024-10-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.70022\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medical Virology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jmv.70022\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"VIROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Virology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jmv.70022","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

国际人乳头瘤病毒(HPV)参考中心每年都会推出全球HPV基因分型能力验证,以提高HPV基因分型服务的精确性和国际标准化。本研究旨在评估2022年和2023年进行的全球HPV基因分型能力验证所达到的能力水平,并评估随时间推移的能力趋势。能力验证小组由 44 份盲法样本组成,其中 40 份样本含有与人类 DNA 结合的 HPV 类型相对应的各种纯化质粒,另外还有 4 份对照样本(1 份阴性对照和 3 份提取对照)。对于 HPV 16 和 HPV 18,检测灵敏度要求为 50 国际单位 (IU)/5 µL ;对于 HPV 6、11、31、33、45、52 和 58,检测灵敏度要求为 500 国际单位/5 µL ;对于其他 HPV 类型,检测灵敏度要求为 500 基因组当量 (GE)/5 µL (包括单次感染和多次感染),同时避免假阳性。2022 年,78 家实验室共提交了 154 组数据;2023 年,81 家实验室提交了 141 组数据。大多数数据集(87%,258/295)采用了市售的 HPV 检测方法。熟练度很普遍,2022 年有 77% 的数据集符合熟练度标准,2023 年有 79% 的数据集符合熟练度标准。假阳性结果从 2022 年的 22% 显著下降到 2023 年的 13%。HPV基因分型服务的高熟练度和不断提高的特异性表明,在进行更可靠的HPV检测方面取得了进展。高准确性对于支持全球消除人乳头瘤病毒和宫颈癌的努力至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Continuous Global Improvement of Human Papillomavirus (HPV) Genotyping Services: The 2022 and 2023 HPV LabNet International Proficiency Studies

The International Human Papillomavirus (HPV) Reference Center launches annual global HPV genotyping proficiency panels to enhance the precision and international standardization of HPV genotyping services. This study aims to assess the proficiency levels achieved in the global HPV genotyping proficiency panels conducted in 2022 and 2023, and to evaluate trends in performance over time. The proficiency panels comprised 44 blinded samples each, including 40 samples containing various purified plasmids corresponding to HPV types combined with human DNA, plus four control samples (one negative control and three extraction controls). Proficiency required a sensitivity of 50 International Units (IU)/5 µL for HPV 16 and HPV 18 500 IU/5 µL for HPVs 6, 11, 31, 33, 45, 52, and 58 and 500 genome equivalents (GE)/5 µL for other HPV types in both single and multiple infections, while avoiding false positivity. In 2022, 78 laboratories submitted a total of 154 data sets, and in 2023, 81 laboratories contributed 141 data sets. Most data sets (87%, 258/295) utilized commercially available HPV assays. Proficiency was common, with 77% of data sets meeting the proficiency criteria in 2022 and 79% in 2023. False positive results significantly decreased from 22% in 2022 to 13% in 2023. The high proficiency and increasing specificity in HPV genotyping services indicates progress toward more reliable HPV testing. High accuracy is crucial for supporting global efforts in HPV and cervical cancer elimination.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Medical Virology
Journal of Medical Virology 医学-病毒学
CiteScore
23.20
自引率
2.40%
发文量
777
审稿时长
1 months
期刊介绍: The Journal of Medical Virology focuses on publishing original scientific papers on both basic and applied research related to viruses that affect humans. The journal publishes reports covering a wide range of topics, including the characterization, diagnosis, epidemiology, immunology, and pathogenesis of human virus infections. It also includes studies on virus morphology, genetics, replication, and interactions with host cells. The intended readership of the journal includes virologists, microbiologists, immunologists, infectious disease specialists, diagnostic laboratory technologists, epidemiologists, hematologists, and cell biologists. The Journal of Medical Virology is indexed and abstracted in various databases, including Abstracts in Anthropology (Sage), CABI, AgBiotech News & Information, National Agricultural Library, Biological Abstracts, Embase, Global Health, Web of Science, Veterinary Bulletin, and others.
期刊最新文献
Concerns on a New Varicella Vaccine Introduced in Korea Molecular Analysis of Coxsackievirus B2 Associated With Severe Symptoms of the Central Nervous System Rhinovirus in pediatric respiratory infections: More than a simple cold Epidemiological Characteristics of Neuro-Specific Antibodies Following Viral Infections Identifying Gaps in Congenital CMV Detection—Implications for the Recent European Consensus Guidelines on Congenital CMV Infection
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1